BiomeBank
PrivateLast Round
Strategic
Apr 17, 2026
Est. Valuation
$42.54M
Total Funding Raised
$19.84M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
BiomeBank is a biotechnology company that develops microbial therapies to treat and prevent diseases by restoring gut microbial ecology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BiomeBank Comparables
Compare BiomeBank with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| EnteroBiotix | 82% | |
| Human Biome S.A. | 79% | |
| Metagen Therapeutics, Inc. | 79% |
BiomeBank Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Apr 17, 2026 | ||||
| Grant | Feb 20, 2024 | ||||
| Convertible Debt | Dec 9, 2022 | ||||
| Grant | Apr 27, 2021 | ||||
| Seed | Dec 4, 2018 |
Key People
Founding team and executive leadership
BiomeBank Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovative Manufacturing Cooperative Research Centre | Grant |
| South Australia Government | Convertible Debt |
| The Hospital Research Foundation Group | Convertible Debt, Seed |
| Ellerston Capital | Convertible Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 17, 2026
Monthly visitors grew 133% MoM, reaching 7.4K.
- Apr 17, 2026
$11M round led by Blackmores Limited
BiomeBank Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about BiomeBank's valuation, stock price, and market status.
Is BiomeBank a public or private company?
BiomeBank is a private company.
What is the current stock price of BiomeBank?
BiomeBank is a private company, so its shares have no public market price. Caplight tracks BiomeBank's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BiomeBank worth (valuation)?
BiomeBank's valuation is estimated at $42.5M based on funding round data.
Can I buy BiomeBank stock?
BiomeBank shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BiomeBank's last funding round?
BiomeBank's most recent funding round was Strategic on April 17, 2026.
Who are the main investors in BiomeBank?
Key investors in BiomeBank include Innovative Manufacturing Cooperative Research Centre, The Hospital Research Foundation Group.
Will BiomeBank IPO soon?
No public IPO plans have been announced for BiomeBank.
How can I track BiomeBank secondary market activity?
Caplight tracks bids, offers, and trades in BiomeBank's shares on secondary markets.